Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P4HB | P07237 | 8/20 | 1.00 |
| ▸ | TP53 | P04637 | 6/20 | 1.00 |
| ▸ | MAPT | P10636 | 5/20 | 1.00 |
| ▸ | USP2 | O75604 | 2/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 1.00 |
| ▸ | THRB | P10828 | 1/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.77 |
| ▸ | MDM2 | Q00987 | 2/20 | 0.75 |
| ▸ | JMJD7 | P0C870 | 1/20 | 0.72 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.72 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.72 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.72 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.72 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.72 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.72 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.72 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.72 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.72 |
| ▸ | HTT | P42858 | 1/20 | 0.72 |
| ▸ | PPP1CA | P62136 | 1/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9965634 | 0.90 | P4HB (0.81) | P4HBTP53MAPTUSP2LMNA | |
| SCHEMBL21842219 | 0.89 | P4HB (0.80) | P4HBTP53MAPTUSP2LMNA | |
| SCHEMBL15783201 | 0.88 | P4HB (0.81) | P4HBTP53MAPTUSP2LMNA | |
| SCHEMBL21842223 | 0.88 | MDM2 (0.82) | P4HBTP53MAPTUSP2LMNA | |
| SCHEMBL15781899 | 0.88 | P4HB (0.79) | P4HBTP53MAPTUSP2LMNA | |
| SCHEMBL15783093 | 0.88 | MAPT (0.80) | P4HBTP53MAPTUSP2LMNA | |
| SCHEMBL1542099 | 0.87 | MAPT (0.80) | P4HBTP53MAPTUSP2LMNA | |
| SCHEMBL21842430 | 0.87 | P4HB (0.81) | P4HBTP53MAPTUSP2LMNA | |
| SCHEMBL15783147 | 0.87 | P4HB (1.00) | P4HBTP53MAPTUSP2LMNA | |
| SCHEMBL9965547 | 0.86 | P4HB (0.75) | P4HBTP53MAPTUSP2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9073858-B2 | Methods of targeted drug development | Errico, Joseph P. (US) | 2015-07-07 | — | — | US | disclosed |
| US-20140194439-A1 | METHODS OF TARGETED DRUG DEVELOPMENT | Errico, Joseph P. (US) | 2014-07-10 | — | — | US | disclosed |
| US-20140163069-A1 | COMPOSITIONS OF TARGETED DRUG DEVELOPMENT | Errico, Joseph P. (US) | 2014-06-12 | — | — | US | disclosed |
| US-20120295890-A1 | GLYCOSAMINOGLYCAN INHIBITORS | Zacharon Pharmaceutical, Inc. (US) | 2012-11-22 | — | — | US | disclosed |
| US-20110301193-A1 | METHODS AND COMPOSITIONS OF TARGETED DRUG DEVELOPMENT | Errico, Joseph P. (US) | 2011-12-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110301193-A1 | METHODS AND COMPOSITIONS OF TARGETED DRUG DEVELOPMENT | EGFR, ERBB2, ERBB3 | P4HB 2320/4885TP53 230/4885MAPT 1076/4885 |
| US-20120295890-A1 | GLYCOSAMINOGLYCAN INHIBITORS | CSGALNACT1, FUT5, ST3GAL3 | P4HB 590/4885TP53 3840/4885MAPT 4328/4885 |
| US-20140163069-A1 | COMPOSITIONS OF TARGETED DRUG DEVELOPMENT | EGFR, ERBB2, ERBB3 | P4HB 2500/4885TP53 95/4885MAPT 1268/4885 |
| US-20140194439-A1 | METHODS OF TARGETED DRUG DEVELOPMENT | EGFR, ERBB2, ERBB4 | P4HB 2095/4885TP53 192/4885MAPT 1499/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.